Citations

Mayo Clinic

Clear

743 citation(s) found for "Ua, Meyer".

Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis
Zhang, Hui , Watanabe, Ryu , Berry, Gerald J. , Liao, Yaping Joyce , Warrington, Kenneth J. , Goronzy, Jörg J. , Weyand, Cornelia M. , Vaglio, Augusto , Warrington, Kenneth J , Goronzy, Jorg , Berry, Gerald J

Proceedings of the National Academy of Sciences | January 23, 2017 | Volume: 114 | Issue: 6 | Pages: No page available

10.1073/pnas.1616848114 | PMID 28115719 Get It

Significance Antigen recognition by the immune system triggers rapid, specific, and protective responses, which are counterbalanced by inhibitory checkpoints to minimize potentially harmful immunity. The programmed death-1/ programmed death ligand-1 (PD-1/PD-L1) checkpoint is overreactive in cancer patients, curbing antitumor immunity. Whether a failing PD-1/PD-L1 checkpoint contributes to spontaneous autoimmune disease in humans is unknown. Here, we found that in patients with the autoimmune vasculitis giant cell arteritis, antigen-presenting cells provide insufficient negative signaling; unleashing highly activated T cells to infiltrate and damage the walls of large arteries. Thus, immunoinhibitory signals protect large arteries against inflammatory attack and checkpoint activation may be a suitable strategy to treat autoimmune vasculitis.
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging
Amin, Mahul B. , Greene, Frederick L. , Edge, Stephen B. , Compton, Carolyn C. , Gershenwald, Jeffrey E., Brookland, Robert K., Meyer, Laura, Gress, Donna M., Byrd, David R. , Winchester, David P., Gershenwald, Jeffrey E.

CA: A Cancer Journal for Clinicians | January 17, 2017 | Volume: 67 | Issue: 2 | Pages: 93-99

10.3322/caac.21388 | PMID 28094848 Get It

Abstract The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM‐based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual , the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a “population‐based” to a more “personalized” approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge‐based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as “what's new” in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93–99. © 2017 American Cancer Society.
Characterizing and predicting the Nelson-Salassa syndrome
Graffeo, Christopher S. , Perry, Avital , Meyer, Fredric B. , Atkinson, John L. D., Erickson, Dana , Nippoldt, Todd B., Pollock, Bruce E. , Carlstrom, Lucas P. , Young, William F. , Gompel, Jamie J. Van

Journal of Neurosurgery | January 13, 2017 | Volume: 127 | Issue: 6 | Pages: 1277-1287

10.3171/2016.9.jns161163 | PMID 28084914 Get It

OBJECTIVENelson-Salassa syndrome (NSS) is a rare consequence of bilateral adrenalectomy (ADX) for refractory hypercortisolism due to Cushing disease (CD). Although classically defined by rapid growth of a large, invasive, adrenocorticotropin hormone (ACTH)–secreting pituitary tumor after bilateral ADX that causes cutaneous hyperpigmentation, visual disturbance, and high levels of ACTH, clinical experience suggests more variability.METHODSThe authors conducted a retrospective chart review of all patients 18 years and older with a history of bilateral ADX for CD, adequate pituitary MRI, and at least 2 years of clinical follow-up. Statistical tests included Student's t-test, chi-square test, Fisher's exact test, multivariate analysis, and derived receiver operating characteristic curves.RESULTSBetween 1956 and 2015, 302 patients underwent bilateral ADX for the treatment of hypercortisolism caused by CD; 88 had requisite imaging and follow-up (mean 16 years). Forty-seven patients (53%) had radiographic progression of pituitary disease and were diagnosed with NSS. Compared with patients who did not experience progression, those who developed NSS were significantly younger at the time of CD diagnosis (33 vs 44 years, p = 0.007) and at the time of bilateral ADX (35 vs 49 years, p = 0.007), had larger tumors at the time of CD diagnosis (6 mm vs 1 mm, p = 0.03), and were more likely to have undergone external-beam radiation therapy (EBRT, 43% vs 12%, p = 0.005). Among NSS patients, the mean tumor growth was 7 mm/yr (SE 6 mm/yr); the median tumor growth was 3 mm/yr. Prevalence of pathognomonic symptoms was low; the classic triad occurred in 9%, while hyperpigmentation without visual field deficit was observed in 23%, and 68% remained asymptomatic despite radiographic disease progression. NSS required treatment in 14 patients (30%).CONCLUSIONSNSS is a prevalent sequela of CD after bilateral ADX and affects more than 50% of patients. However, although radiological evidence of NSS is common, it is most often clinically indolent, with only a small minority of patients developing the more aggressive disease phenotype characterized by clinically meaningful symptoms and indications for treatment. Young age at the time of CD diagnosis or treatment with bilateral ADX, large tumor size at CD diagnosis, and EBRT are associated with progression to NSS and may be markers of aggressiveness.
Reactivation of seizure‐related changes to interictal spike shape and synchrony during postseizure sleep in patients
Bower, Mark R. , Kucewicz, Michał T. , Louis, Erik K. St. , Meyer, Fredric B. , Marsh, W. Richard , Stead, Matt, St Louis, Erik K, Worrell, Gregory A. , St Louis, E K , Kucewicz, Michal

Epilepsia | November 18, 2016 | Volume: 58 | Issue: 1 | Pages: 94-104

10.1111/epi.13614 | PMID 27859029 Get It

SummaryObjectiveLocal field potentials (LFPs) arise from synchronous activation of millions of neurons, producing seemingly consistent waveform shapes and relative synchrony across electrodes. Interictal spikes (IISs) are LFPs associated with epilepsy that are commonly used to guide surgical resection. Recently, changes in neuronal firing patterns observed in the minutes preceding seizure onset were found to be reactivated during postseizure sleep, a process called seizure‐related consolidation (SRC), due to similarities with learning‐related consolidation. Because IISs arise from summed neural activity, we hypothesized that changes in IIS shape and relative synchrony would be observed in the minutes preceding seizure onset and would be reactivated preferentially during postseizure slow‐wave sleep (SWS).MethodsScalp and intracranial recordings were obtained continuously across multiple days from clinical macroelectrodes implanted in patients undergoing treatment for intractable epilepsy. Data from scalp electrodes were used to stage sleep. Data from intracranial electrodes were used to detect IISs using a previously established algorithm. Partial correlations were computed for sleep and wake periods before and after seizures as a function of correlations observed in the minutes preceding seizures. Magnetic resonance imaging (MRI) and computed tomography (CT) scans were co‐registered with electroencephalography (EEG) to determine the location of the seizure‐onset zone (SOZ).ResultsChanges in IIS shape and relative synchrony were observed on a subset of macroelectrodes minutes before seizure onset, and these changes were reactivated preferentially during postseizure SWS. Changes in synchrony were greatest for pairs of electrodes where at least one electrode was located in the SOZ.SignificanceThese data suggest preseizure changes in neural activity and their subsequent reactivation occur across a broad spatiotemporal scale: from single neurons to LFPs, both within and outside the SOZ. The preferential reactivation of seizure‐related changes in IISs during postseizure SWS adds to a growing body of literature suggesting that pathologic neural processes may utilize physiologic mechanisms of synaptic plasticity.
A comparison of tissue-based and recombinant protein–based assays for detecting PCA-Tr/DNER-IgG
Alfugham, Nora, Roforth, Matthew M., Komorowski, Lars , Ott, Anthonina, Meyer, Wolfgang , Probst, Christian , Lennon, Vanda A. , Pittock, Sean J. , McKeon, Andrew , Roforth, Matthew, Pittock, S J , McKeon, Andrew

Neurology Neuroimmunology & Neuroinflammation | October 29, 2016 | Volume: 3 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000294 | PMID 27844036 Get It

Vascular Access for Hemodialysis and Value-Based Purchasing for ESRD
Cheung, Alfred K. , Meyer, Timothy W. , Nath, Karl A. , Mehrotra, Rajnish

Journal of the American Society of Nephrology | October 6, 2016 | Volume: 28 | Issue: 2 | Pages: 395-397

10.1681/asn.2016070769 | PMID 28143965 Get It

Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept
Klein, Franziska J., Runte, Kilian , Lobel, Robert, Ashikaga, Takamuru, Lerman, Lilach O. , LeWinter, Martin M. , Meyer, Markus , Bell, Stephen P.

American Journal of Physiology-Heart and Circulatory Physiology | September 2, 2016 | Volume: 311 | Issue: 4 | Pages: H1031-H1039

10.1152/ajpheart.00301.2016 | PMID 27591220 Get It

Lowering the heart rate is considered to be beneficial in heart failure (HF) with reduced ejection fraction (HFrEF). In a dilated left ventricle (LV), pharmacological heart rate lowering is associated with a reduction in LV chamber size. In patients with HFrEF, this structural change is associated with better survival. HF with preserved ejection fraction (HFpEF) is increasingly prevalent but, so far, without any evidence-based treatment. HFpEF is typically associated with LV concentric remodeling and hypertrophy. The effects of heart rate on this structural phenotype are not known. Analogous with the benefits of a low heart rate on a dilated heart, we hypothesized that increased heart rates could lead to potentially beneficial remodeling of a concentrically hypertrophied LV. This was explored in an established porcine model of concentric LV hypertrophy and fibrosis. Our results suggest that a moderate increase in heart rate can be used to reduce wall thickness, normalize LV chamber volumes, decrease myocardial fibrosis, and improve LV compliance. Our results also indicate that the effects of heart rate can be titrated, are reversible, and do not induce HF. These findings may provide the rationale for a novel therapeutic approach for HFpEF and its antecedent disease substrate. Listen to this article’s corresponding podcast at http://ajpheart.podbean.com/e/heart-rate-modeling/ .
Insulin does not stimulate muscle protein synthesis during increased plasma branched-chain amino acids alone but still decreases whole body proteolysis in humans
Everman, Sarah , Tran, Lee , Hoffman, Nyssa, Carroll, Chad C. , Dedmon, William L., Katsanos, Christos S. , Meyer, Christian , Katsanos, Christos S

American Journal of Physiology-Endocrinology and Metabolism | August 16, 2016 | Volume: 311 | Issue: 4 | Pages: E671-E677

10.1152/ajpendo.00120.2016 | PMID 27530230 Get It

Insulin stimulates muscle protein synthesis when the levels of total amino acids, or at least the essential amino acids, are at or above their postabsorptive concentrations. Among the essential amino acids, branched-chain amino acids (BCAA) have the primary role in stimulating muscle protein synthesis and are commonly sought alone to stimulate muscle protein synthesis in humans. Fourteen healthy young subjects were studied before and after insulin infusion to examine whether insulin stimulates muscle protein synthesis in relation to the availability of BCAA alone. One half of the subjects were studied in the presence of postabsorptive BCAA concentrations (control) and the other half in the presence of increased plasma BCAA (BCAA). Compared with that prior to the initiation of the insulin infusion, fractional synthesis rate of muscle protein (%/h) did not change ( P > 0.05) during insulin in either the control (0.04 ± 0.01 vs 0.05 ± 0.01) or the BCAA (0.05 ± 0.02 vs. 0.05 ± 0.01) experiments. Insulin decreased ( P < 0.01) whole body phenylalanine rate of appearance (μmol·kg−1·min−1), indicating suppression of muscle proteolysis, in both the control (1.02 ± 0.04 vs 0.76 ± 0.04) and the BCAA (0.89 ± 0.07 vs 0.61 ± 0.03) experiments, but the change was not different between the two experiments ( P > 0.05). In conclusion, insulin does not stimulate muscle protein synthesis in the presence of increased circulating levels of plasma BCAA alone. Insulin's suppressive effect on proteolysis is observed independently of the levels of circulating plasma BCAA.
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Bohlke, Kari , Armstrong, Deborah K. , Cliby, William A. , Dizon, Don S. , Kash, Joseph J., Meyer, Larissa A. , Moore, Kathleen N. , Olawaiye, Alexander , Oldham, Jessica, Salani, Ritu , Sparacio, Dee, Tew, William P. , Vergote, Ignace , Edelson, Mitchell I. , Wright, Alexi A, Bookman, Michael A. , Coleman, Robert L. , Olawaiye, Alexander B, Wright, Alexi A. , Moore, Kathleen , Meyer, Larissa A , Edelson, Mitchell I

Journal of Clinical Oncology | August 9, 2016 | Volume: 34 | Issue: 28 | Pages: 3460-3473

10.1200/jco.2016.68.6907 | PMID 27502591 Get It

Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality. Recommendations All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a gynecologic oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and pelvis, and chest imaging (CT preferred). Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to < 1 cm of residual disease (ideally to no visible disease) should receive neoadjuvant chemotherapy. Women who are fit for primary cytoreductive surgery, and with potentially resectable disease, may receive either neoadjuvant chemotherapy or primary cytoreductive surgery. However, primary cytoreductive surgery is preferred if there is a high likelihood of achieving cytoreduction to < 1 cm (ideally to no visible disease) with acceptable morbidity. Before neoadjuvant chemotherapy is delivered, all patients should have confirmation of an invasive ovarian, fallopian tube, or peritoneal cancer. Additional information is available at www.asco.org/NACT-ovarian-guideline and www.asco.org/guidelineswiki .
Contemporary analysis of the intraoperative and perioperative complications of neurosurgical procedures performed in the sitting position
Mallory, Grant W., Abcejo, Arnoley S., Pasternak, Jeffrey J., Atkinson, John L. D., Meyer, Fredric B. , Marsh, W. Richard , Link, Michael J. , Perkins, William J., Pasternak, Jeffrey, Perkins, William, Himes, Benjamin , Clarke, Michelle J. , Gompel, Jamie J. Van

Journal of Neurosurgery | August 5, 2016 | Volume: 127 | Issue: 1 | Pages: 182-188

10.3171/2016.5.jns152328 | PMID 27494821 Get It

OBJECTIVE Historically, performing neurosurgery with the patient in the sitting position offered advantages such as improved visualization and gravity-assisted retraction. However, this position fell out of favor at many centers due to the perceived risk of venous air embolism (VAE) and other position-related complications. Some neurosurgical centers continue to perform sitting-position cases in select patients, often using modern monitoring techniques that may improve procedural safety. Therefore, this paper reports the risks associated with neurosurgical procedures performed in the sitting position in a modern series. METHODS The authors reviewed the anesthesia records for instances of clinically significant VAE and other complications for all neurosurgical procedures performed in the sitting position between January 1, 2000, and October 8, 2013. In addition, a prospectively maintained morbidity and mortality log of these procedures was reviewed for instances of subdural or intracerebral hemorrhage, tension pneumocephalus, and quadriplegia. Both overall and specific complication rates were calculated in relation to the specific type of procedure. RESULTS In a series of 1792 procedures, the overall complication rate related to the sitting position was 1.45%, which included clinically significant VAE, tension pneumocephalus, and subdural hemorrhage. The rate of any detected VAE was 4.7%, but the rate of VAE requiring clinical intervention was 1.06%. The risk of clinically significant VAE was highest in patients undergoing suboccipital craniotomy/craniectomy with a rate of 2.7% and an odds ratio (OR) of 2.8 relative to deep brain stimulator cases (95% confidence interval [CI] 1.2–70, p = 0.04). Sitting cervical spine cases had a comparatively lower complication rate of 0.7% and an OR of 0.28 as compared with all cranial procedures (95% CI 0.12–0.67, p < 0.01). Sitting cervical cases were further subdivided into extradural and intradural procedures. The rate of complications in intradural cases was significantly higher (OR 7.3, 95% CI 1.4–39, p = 0.02) than for extradural cases. The risk of VAE in intradural spine procedures did not differ significantly from sitting suboccipital craniotomy/craniectomy cases (OR 0.69, 95% CI 0.09–5.4, p = 0.7). Two cases (0.1%) had to be aborted intraoperatively due to complications. There were no instances of intraoperative deaths, although there was a single death within 30 days of surgery. CONCLUSIONS In this large, modern series of cases performed in the sitting position, the complication rate was low. Suboccipital craniotomy/craniectomy was associated with the highest risk of complications. When appropriately used with modern anesthesia techniques, the sitting position provides a safe means of surgical access.